Hållbar UPPHANDLING
Ett samarbete mellan Sveriges regioner

Summary of follow-up results

Below is a summary of a follow-up of sustainability requirements for a supplier to Sweden's regions. The summary is a presentation of the results of the audit and the activities resulting from it. The summary has been added as new activities linked to the follow-up have been carried out, until all possible deviations have been handled and the follow-up is considered completed.

For questions regarding the summary, contact the Regional Office for Sustainable Procurement

www.husr.se

Log

Last updated	2025-01-24

General Information

Supplier	Baxter Medical AB
Regions with agreements	Region Västra Götaland
Risk area	Medicines
Product	Cycostatic drug
Type of follow-up	Office Audit
Requirements	Sustainable supply chains and systematic environmental work
Audit date	2024-11-21
For more info	For more information or a report, please contact Jenny Forsell Skoog, jenny.forsell.skoog@vgregion.se

Audit results

Summary of the audit

Baxter participated in a pleasant and transparent audit in which the auditors had access to the documentation and were able to conduct the interviews with managers needed to assess compliance with the terms of the contract.

During the audit, however, it appears that they have not had time to obtain information about the production site for a new sample that was announced on 15/11. The participants do not have the expertise locally and therefore made an effort to bring in the right expertise during the day to answer product-specific questions.

Baxter has begun a systematic process to comply with the terms and conditions of the agreement. Baxter is deemed to have deviations from the routine requirements; Forwarding of commitments, division of responsibilities, risk analysis, follow-up and deviation management.

Audit results

Sustainable supply chains	Assessment*
1. Policy commitment	
2. Forwarding of comittments	
3. Division of responsibilities	
4. Risk analysis	
5. Follow-up	
6. Deviation management	
7. Access to production facility	

Environmental requirements	Assessment*
1. Systematic environmental work	
2. Environmental policy	
3. Environmental investigation	
4. Goals and action plans environment	

	Explanations	
	Deviation	
	No anomalies detected	

*For a detailed description, see Appendix 1. Deviations

Next steps	Action plan approved, re-revision recommended.

Appendix 1 - Deviations

	Sustainable supply chains
Deviation	Baxter has not disclosed how the Terms of Agreement are passed on further down the supply chain.
Supplier's action	Baxter will demonstrate that for each purchase, it issues a purchase order ("PO") with terms and conditions incorporating EU and US ESG requirements into its standard terms and conditions, which are available on Baxter's external website at http://www.baxter.com/partners-suppliers/baxtersuppliers/purchase-order-terms-conditions. • Baxter will demonstrate that it disseminates ESG requirements through eh issuance of each PO. • Baxter will demonstrate that its purchasing templates include ESG language, as well as Ethics and Compliance Standards for Suppliers, which also addresses ESG matters. • Baxter will demonstrate that during the RFP process, it shares with incumbent suppliers its Global Suppliers Standards Manual (GSSM), available on Baxter's external website. • Baxter will demonstrate that its policies and procedures undergo period reviews. • Baxter will demonstrate that, on periodic basis, its ESG team monitors suppliers' compliance.
Timetable	April 2025
Deviation	Baxter has not explained who is ultimately responsible for matters relating to the terms of the agreement, nor is it possible to present an organizational chart that shows the division of responsibilities.
Supplier's action	Baxter will demonstrate organizational responsibilities among its leadership team for ESG matters.
Timetable	April 2025
Deviation	Baxter has not reported on systematic work on risk analysis within the company. Baxter has also not disclosed risks associated with goods within the contract.
Supplier's action	Baxter will demonstrate the Corporate Responsibly organizational structure, and its use of external partners to follow up on suppliers' compliance.
Timetable	April 2025

Deviation	Baxter has not disclosed activities that have been taken to systematically follow up compliance with the terms of the agreement in its own operations or in the supply chain of the sample product
Supplier's action	Baxter will explain its follow up activities both within internal operations and in conjunction with the external service provider.
Timetable	April 2025
Deviation	Baxter has not disclosed whether any deviations in compliance with the terms of the contract have occurred during the term of the agreement, related to the goods or services covered by the agreement. Baxter has not disclosed systematic deviation management in its own operations or in the supply chain given the severity of the deviation.
Supplier's action	Baxter will explain its corrective action processes, both within internal operations and in conjunction with the external service provider.
Timetable	April 2025